Literature DB >> 15612682

Structure-based design of potent, conformationally constrained Smac mimetics.

Haiying Sun1, Zaneta Nikolovska-Coleska, Chao-Yie Yang, Liang Xu, Meilan Liu, York Tomita, Hongguang Pan, Yoshiko Yoshioka, Krzysztof Krajewski, Peter P Roller, Shaomeng Wang.   

Abstract

A successful structure-based design and synthesis of a class of highly potent conformationally constrained Smac mimetics is described. The most potent compound has a Ki value of 25 nM binding to the XIAP BIR3 protein and is 23 times more potent than natural Smac peptides. These potent Smac mimetics can serve as powerful chemical and pharmacological tools to further elucidate the role of Smac and its cellular binding partners in apoptosis regulation and may be developed as a new class of anti-cancer drugs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15612682     DOI: 10.1021/ja047438+

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  50 in total

1.  Smac-mimetic-induced epithelial cell death reduces the growth of renal cysts.

Authors:  Lucy X Fan; Xia Zhou; William E Sweeney; Darren P Wallace; Ellis D Avner; Jared J Grantham; Xiaogang Li
Journal:  J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 10.121

Review 2.  Targeting protein-protein interactions for cancer therapy.

Authors:  David C Fry; Lyubomir T Vassilev
Journal:  J Mol Med (Berl)       Date:  2005-11-11       Impact factor: 4.599

Review 3.  Induction of apoptosis in lymphoid and myeloid leukemia.

Authors:  Aaron D Schimmer
Journal:  Curr Oncol Rep       Date:  2006-11       Impact factor: 5.075

4.  Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP.

Authors:  Haiying Sun; Zaneta Nikolovska-Coleska; Jianfeng Lu; Jennifer L Meagher; Chao-Yie Yang; Su Qiu; York Tomita; Yumi Ueda; Sheng Jiang; Krzysztof Krajewski; Peter P Roller; Jeanne A Stuckey; Shaomeng Wang
Journal:  J Am Chem Soc       Date:  2007-11-14       Impact factor: 15.419

5.  Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis.

Authors:  Yao Dai; Meilan Liu; Wenhua Tang; Jeffrey DeSano; Ezra Burstein; Mary Davis; Kenneth Pienta; Theodore Lawrence; Liang Xu
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

6.  Natural IAP inhibitor Embelin enhances therapeutic efficacy of ionizing radiation in prostate cancer.

Authors:  Yao Dai; Jeffrey Desano; Yang Qu; Wenhua Tang; Yang Meng; Theodore S Lawrence; Liang Xu
Journal:  Am J Cancer Res       Date:  2011       Impact factor: 6.166

7.  Structure-based design, synthesis, evaluation, and crystallographic studies of conformationally constrained Smac mimetics as inhibitors of the X-linked inhibitor of apoptosis protein (XIAP).

Authors:  Haiying Sun; Jeanne A Stuckey; Zaneta Nikolovska-Coleska; Dongguang Qin; Jennifer L Meagher; Su Qiu; Jianfeng Lu; Chao-Yie Yang; Naoyuki G Saito; Shaomeng Wang
Journal:  J Med Chem       Date:  2008-11-27       Impact factor: 7.446

8.  Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B.

Authors:  Yao Dai; Theodore S Lawrence; Liang Xu
Journal:  Am J Transl Res       Date:  2009-01-01       Impact factor: 4.060

9.  Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α.

Authors:  Dennis L Buckley; Jeffrey L Gustafson; Inge Van Molle; Anke G Roth; Hyun Seop Tae; Peter C Gareiss; William L Jorgensen; Alessio Ciulli; Craig M Crews
Journal:  Angew Chem Int Ed Engl       Date:  2012-10-12       Impact factor: 15.336

10.  A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB.

Authors:  Yao Dai; Meilan Liu; Wenhua Tang; Yongming Li; Jiqin Lian; Theodore S Lawrence; Liang Xu
Journal:  BMC Cancer       Date:  2009-11-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.